SCHEMBL2194472

SCHEMBL2194472

Fc1ccc(Nc2ncnc3sc4c(c23)CCc2nn(CCN3CCSCC3)cc2-4)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 18/20 0.50
FGFR1 P11362 1/20 0.49
CCNA2 P20248 1/20 0.49
CDK2 P24941 1/20 0.49
CCNA1 P78396 1/20 0.49
MAPT P10636 2/20 0.40
RAF1 P04049 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
MAP2K1 Q02750 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CIT O14578 1/20 0.40
GAK O14976 1/20 0.40
EPHB6 O15197 1/20 0.40
ABCC4 O15439 1/20 0.40
DAPK3 O43293 1/20 0.40
RIPK2 O43353 1/20 0.40
NR1I2 O75469 1/20 0.40
RPS6KA4 O75676 1/20 0.40
STK17B O94768 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194272 0.94 EGFR (0.54) EGFRFGFR1CCNA2CDK2CCNA1
SCHEMBL2196230 0.93 FGFR1 (0.54) EGFRFGFR1CCNA2CDK2CCNA1
SCHEMBL2194084 0.92 CCNA2 (0.51) EGFRFGFR1CCNA2CDK2CCNA1
SCHEMBL2196141 0.92 EGFR (0.51) EGFRFGFR1CCNA2CDK2CCNA1
SCHEMBL2196142 0.92 CCNA2 (0.50) EGFRFGFR1CCNA2CDK2CCNA1
SCHEMBL2192018 0.92 EGFR (0.49) EGFRFGFR1CCNA2CDK2CCNA1
SCHEMBL2195974 0.90 CCNA2 (0.48) EGFRFGFR1CCNA2CDK2CCNA1
SCHEMBL2194636 0.89 EGFR (0.47) EGFRFGFR1CCNA2CDK2CCNA1
SCHEMBL2192859 0.88 EGFR (0.54) EGFRFGFR1CCNA2CDK2CCNA1
SCHEMBL2087273 0.88 EGFR (0.54) EGFRFGFR1CCNA2CDK2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207172-B2 Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-26 US disclosed
US-8207172-B2 Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-26 US disclosed
US-8207172-B2 Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-26 US disclosed
US-20110172224-A1 NOVEL HETEROCYCLES BAYER PHARMACEUTICALS CORPORATION (US) 2011-07-14 US disclosed
US-20110172224-A1 NOVEL HETEROCYCLES BAYER PHARMACEUTICALS CORPORATION (US) 2011-07-14 US disclosed
US-20110172224-A1 NOVEL HETEROCYCLES BAYER PHARMACEUTICALS CORPORATION (US) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172224-A1 NOVEL HETEROCYCLES CCNI, PCNA, CCNA1 EGFR 2146/4885FGFR1 1058/4885CCNA2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.